Skandinaviska Enskilda Banken Ab (Publ) Immunovant, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $21.6 Billion
- Q4 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Immunovant, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 35,316 shares of IMVT stock, worth $971,543. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,316
Previous 88,468
60.08%
Holding current value
$971,543
Previous $2.43 Million
60.09%
% of portfolio
0.0%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding IMVT
# of Institutions
215Shares Held
66.4MCall Options Held
2.3MPut Options Held
631K-
Vanguard Group Inc Valley Forge, PA6.66MShares$183 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.35MShares$120 Million4.41% of portfolio
-
Armistice Capital, LLC New York, NY3.55MShares$97.6 Million1.62% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.33MShares$91.6 Million0.06% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...